Gilead Sciences GILD
US equityMarket cap rank #82Drug Manufacturers - GeneralCAR-T TherapyInfectious DiseaseCancer Research
$166.89 −$0.68 (-0.41%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $166.89 0.00%
Open$164.11
Prev close$167.57
Day range$164.00 – $169.06
Volume5.82M
Market cap$207.00B
P/E (TTM)–
Dividend yield1.95%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$8.30B+6.8% YoY
Operating profit$3.48B-0.5% YoY
Net profit$2.43B-20.4% YoY
Diluted EPS$1.94-20.2% YoY
Free cash flow$4.80B+21.1% YoY
Operating cash flow$5.04B
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin79.9%
Operating margin37.8%
Net margin-12.5%
Return on equity-22.3%
Return on assets-7.0%
Return on invested capital-8.0%
Current ratio1.38
Liabilities / assets74.8%
Cash & investments$6.44B
Total debt$26.23B
Net cash (debt)-$19.79B
Free cash flow / sales44.5%
Where the revenue comes from
Quarter 2026/Q2
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $8.30B | $7.80B | $6.96B | $29.44B | $7.93B |
| Total Operating Revenue | $8.30B | $7.80B | $6.96B | $29.44B | $7.92B |
| Cost of Revenue | $1.57B | $1.58B | $1.45B | $6.23B | $1.62B |
| Gross Profit | $6.73B | $6.22B | $5.52B | $23.21B | $6.30B |
| Operating Expense | $3.25B | $3.69B | $2.82B | $11.51B | $3.31B |
| Selling and Admin Expenses | $1.64B | $1.92B | $1.45B | $5.71B | $1.73B |
| -Selling & Marketing Expense | $946.00M | $1.01B | $898.00M | $3.52B | $1.08B |
| -General & Admin Expense | $695.00M | $910.00M | $553.00M | $2.19B | $652.00M |
| Research & Development | $1.61B | $1.76B | $1.37B | $5.80B | $1.58B |
| Operating Profit | $3.48B | $2.54B | $2.69B | $11.70B | $2.99B |
| Net Non-Operating Interest Income (Expense) | -$228.00M | -$202.00M | -$145.00M | -$675.00M | -$160.00M |
| Non-Operating Interest Income | $41.00M | $45.00M | $95.00M | $349.00M | $95.00M |
| Non-Operating Interest Expense | $269.00M | $247.00M | $240.00M | $1.02B | $255.00M |
| Other Income (Expense) | -$189.00M | -$12.59B | $33.00M | -$1.23B | -$750.00M |
| Gain on Sale of Security | -$164.00M | $343.00M | $142.00M | $451.00M | $253.00M |
| Special Income (Charges) | -$18.00M | -$12.93B | -$107.00M | -$1.68B | -$1.01B |
| -Less:Impairment of Capital Assets | $0.00 | $1.75B | – | – | – |
| -Less:Other Special Charges | $18.00M | $11.18B | $107.00M | $1.02B | $539.00M |
| Other Non-Operating Income (Expenses) | -$7.00M | -$1.00M | -$2.00M | -$1.00M | $2.00M |
| Pretax Profit | $3.06B | -$10.25B | $2.58B | $9.80B | $2.08B |
| Tax | $634.00M | $242.00M | $559.00M | $1.29B | -$105.00M |
| Net Profit | $2.43B | -$10.50B | $2.02B | $8.51B | $2.18B |
| Profit from Continuing Operations | $2.43B | -$10.50B | $2.02B | $8.51B | $2.18B |
| Net Income to Parent Company | $2.43B | -$10.50B | $2.02B | $8.51B | $2.18B |
| Net Income to Common Stockholders | $2.43B | -$10.50B | $2.02B | $8.51B | $2.18B |
| Basic EPS | $1.96 | -$8.45 | $1.63 | $6.84 | $1.76 |
| Diluted EPS | $1.94 | -$8.45 | $1.61 | $6.78 | $1.74 |
| Dividend Per Share | $0.82 | $0.82 | $0.82 | $3.16 | $0.79 |
| -Less:Write Off | – | $1.75B | – | $590.00M | $400.00M |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $66.00M | – |
| Minority Interests | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $51.41B | $49.36B | $56.28B | $59.02B | $59.02B |
| Total Current Assets | $16.55B | $13.95B | $18.64B | $18.34B | $18.34B |
| Cash and Cash Equivalents & Short-Term Investments | $6.44B | $3.18B | $7.64B | $9.61B | $9.61B |
| -Cash and Cash Equivalents | $6.44B | $3.18B | $7.63B | $7.56B | $7.56B |
| -Short Term Investments | $0.00 | $0.00 | $15.00M | $2.05B | $2.05B |
| Receivables | $5.01B | $5.06B | $4.74B | $4.91B | $4.91B |
| -Accounts Receivable | $5.01B | $5.06B | $4.74B | $4.91B | $4.91B |
| Inventory | $1.90B | $1.95B | $1.91B | $1.77B | $1.77B |
| Other Current Assets | $3.21B | $3.76B | $4.34B | $1.14B | $1.14B |
| Total Non-Current Assets | $34.85B | $35.42B | $37.64B | $40.68B | $40.68B |
| Net PPE | $5.95B | $5.83B | $5.64B | $5.61B | $5.61B |
| -Gross PPE | $8.95B | $8.71B | $8.42B | $8.30B | $8.30B |
| -Accumulated Depreciation | -$3.00B | -$2.87B | -$2.78B | -$2.70B | -$2.70B |
| Investments and Advances | $0.00 | $0.00 | $983.00M | $2.97B | $2.97B |
| Goodwill and Other Intangible Assets | $21.74B | $22.35B | $24.70B | $25.29B | $25.29B |
| -Goodwill | $8.31B | $8.31B | $8.31B | $8.31B | $8.31B |
| -Other Intangible Assets | $13.42B | $14.03B | $16.38B | $16.98B | $16.98B |
| Non-Current Deferred Assets | $2.27B | $2.49B | $1.77B | $1.96B | $1.96B |
| Other Non-Current Assets | $4.90B | $4.75B | $4.55B | $4.85B | $4.85B |
| Total Liabilities | $38.45B | $37.62B | $32.85B | $36.41B | $36.41B |
| Total Current Liabilities | $12.00B | $11.02B | $9.48B | $11.81B | $11.81B |
| Payables | $934.00M | $674.00M | $645.00M | $807.00M | $807.00M |
| -Accounts Payable | $934.00M | $674.00M | $645.00M | $715.00M | $715.00M |
| Current Accrued Expenses | $4.62B | $4.23B | $4.12B | $4.34B | $4.34B |
| Short-Term Debt and Capital Lease Obligation | $2.42B | $2.41B | $1.31B | $2.81B | $2.81B |
| -Current Debt | $2.42B | $2.41B | $1.31B | $2.81B | $2.81B |
| Other Current Liabilities | $4.03B | $3.70B | $3.40B | $2.24B | $2.24B |
| Total Non-Current Liabilities | $26.45B | $26.60B | $23.37B | $24.59B | $24.59B |
| Long Term Accounts Payable and Other Payables | $974.00M | $943.00M | $918.00M | $896.00M | $896.00M |
| Long Term Debt and Capital Lease Obligation | $23.82B | $23.83B | $20.86B | $22.13B | $22.13B |
| -Long Term Debt | $23.82B | $23.83B | $20.86B | $22.13B | $22.13B |
| Non-Current Deferred Liabilities | $318.00M | $333.00M | $392.00M | $402.00M | $402.00M |
| Other Non-Current Liabilities | $1.35B | $1.49B | $1.20B | $1.17B | $1.17B |
| Total Equity | $12.95B | $11.74B | $23.43B | $22.62B | $22.62B |
| Stockholders' Equity | $13.04B | $11.83B | $23.52B | $22.70B | $22.70B |
| Capital Stock | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| -Common Stock | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $9.84B | $9.53B | $9.31B | $8.93B | $8.93B |
| Retained Earnings | $3.11B | $2.20B | $14.13B | $13.73B | $13.73B |
| Gains/Losses Not Affecting Retained Earnings | $89.00M | $95.00M | $78.00M | $39.00M | $39.00M |
| Minority Interests | -$84.00M | -$84.00M | -$84.00M | -$84.00M | -$84.00M |
| -Available for Sale Securities | – | – | $983.00M | $2.97B | $2.97B |
| Prepaid Assets | – | – | – | $899.00M | $899.00M |
| -Total Tax Payable | – | – | – | $92.00M | $92.00M |
| Current Provisions | – | – | – | $321.00M | $321.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $5.04B | $3.57B | $2.54B | $10.02B | $3.33B |
| Net cash flow from continuing operations | $5.04B | $3.57B | $2.54B | $10.02B | $3.33B |
| Net Income from Continuing Operations | $2.43B | -$10.50B | $2.02B | $8.51B | $2.18B |
| Gain/Loss from Continuing Operations | $164.00M | -$343.00M | -$142.00M | -$451.00M | -$253.00M |
| Depreciation & Depletion & Amortization | $740.00M | $698.00M | $689.00M | $2.76B | $687.00M |
| Deferred Tax | $202.00M | -$587.00M | $179.00M | $160.00M | -$122.00M |
| Other Non-Cash Items | $251.00M | $12.28B | $290.00M | $1.50B | $806.00M |
| Change in Working Capital | $1.01B | $36.00M | -$711.00M | -$3.95B | -$604.00M |
| -Change in Receivables | $52.00M | -$333.00M | $134.00M | -$367.00M | $179.00M |
| -Change in Inventory | -$252.00M | -$145.00M | -$52.00M | -$1.04B | -$123.00M |
| -Change in Prepaid Assets | $0.00 | -$13.00M | $5.00M | -$311.00M | -$36.00M |
| -Change in Payables and Accrued Expense | $1.01B | $356.00M | -$769.00M | -$126.00M | -$490.00M |
| -Change In Other Working Capital | $204.00M | $171.00M | -$29.00M | -$2.11B | -$134.00M |
| Net cash flow from investing | -$244.00M | -$10.35B | $1.77B | -$4.79B | -$1.84B |
| Net Cash Flow from Continuing Investing Activities | -$243.00M | -$10.35B | $1.77B | -$4.79B | -$1.84B |
| Net PPE Purchase and Sale | -$237.00M | -$140.00M | -$117.00M | -$563.00M | -$205.00M |
| Net Business Purchase and Sale | -$19.00M | -$11.21B | -$109.00M | -$1.07B | -$609.00M |
| Net Investment Purchase and Sale | -$1.00M | $983.00M | $2.01B | -$3.16B | -$1.03B |
| Net Other Investing Changes | $13.00M | $19.00M | -$16.00M | $3.00M | $12.00M |
| Financing Cash Flow | -$1.53B | $2.34B | -$4.24B | -$7.75B | -$1.26B |
| Net Cash Flow from Continuing Financing Activities | -$1.53B | $2.34B | -$4.24B | -$7.75B | -$1.26B |
| Net Issuance Payments Of Debt | -$19.00M | $4.07B | -$2.77B | -$1.79B | -$8.00M |
| Net Common Stock Issuance | -$283.00M | -$346.00M | -$253.00M | -$1.51B | -$198.00M |
| Cash Dividends Paid | -$1.04B | -$1.03B | -$1.04B | -$4.00B | -$994.00M |
| Net Other Financing Charges | -$187.00M | -$349.00M | -$180.00M | -$440.00M | -$63.00M |
| Ending Cash Balance | $6.44B | $3.18B | $7.63B | $7.56B | $7.56B |
| Net Change in Cash | $3.26B | -$4.43B | $75.00M | -$2.52B | $229.00M |
| Beginning Cash Balance | $3.18B | $7.63B | $7.56B | $9.99B | $7.33B |
| Effect of Exchange Rate Changes | -$4.00M | -$19.00M | -$11.00M | $92.00M | $5.00M |
| Free Cash Flow | $4.80B | $3.43B | $2.43B | $9.46B | $3.12B |
No comments yet — be the first to weigh in on GILD.
Sign in to join the discussion.